

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

CHEMGENEX PHARMACEUTICALS LTD

ABN 79 000 248 304

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|--|
| 1 | +Class of +securities issued or to be issued | (A) ISSUE ORDINARY SHARES UPON CONVERSION OF UNLISTED ESOP OPTIONS.

(B) ISSUE OF UNLISTED ESOP OPTIONS TO NEWLY APPOINTED EXECUTIVE.

(C) LAPSING OF UNLISTED ESOP OPTIONS. |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | (A) ISSUE OF 300,000 ORDINARY SHARES.

(B) ISSUE OF 2,376,000 UNLISTED ESOP OPTIONS.

(C) LAPSING OF 2,139,500 UNLISTED ESOP OPTIONS. |

+ See chapter 19 for defined terms.

3	Principal terms of the ⁺ securities (eg, if options, exercise price and expiry date; if partly paid ⁺ securities, the amount outstanding and due dates for payment; if ⁺ convertible securities, the conversion price and dates for conversion)	<p>(A) 300,000 FULLY PAID ORDINARY SHARES ISSUED ON CONVERSION OF 300,000 UNLISTED ESOP OPTIONS WITH VARIOUS EXERCISE PRICES.</p> <p>(B) 2,376,000 UNLISTED ESOP OPTIONS HAVE BEEN GRANTED WITH AN EXERCISE PRICE OF \$0.585, AND AN EXPIRY DATE OF 30 NOVEMBER 2013. THESE OPTIONS VEST OVER A FOUR YEAR PERIOD UNTIL 30 NOVEMBER 2012.</p> <p>(C) 2,139,500 UNLISTED ESOP OPTIONS WITH A RANGE OF EXERCISE PRICES, EXERCISE DATES AND VESTING SCHEDULES HELD BY FORMER STAFF AND CONSULTANTS TO THE COMPANY HAVE LAPSSED.</p>
4	<p>Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>(A) ORDINARY SHARES RANK EQUALLY WITH EXISTING SHARES.</p> <p>(B) ESOP OPTIONS HAVE NO ENTITLEMENTS UNTIL CONVERTED TO ORDINARY SHARES</p> <p>(C) NA</p>
5	Issue price or consideration	<p>(A) TOTAL CONSIDERATION FOR CONVESRION OF ESOP OPTIONS TO ORDINARY SHARES \$148,650.00 (SEE ITEM 3 ABOVE).</p> <p>(B) EXERCISE PRICE FOR THIS TRANCHE OF UNLISTED ESOP OPTIONS IS \$0.585.</p> <p>(C) NA</p>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<p>(A) CONVERSION OF UNLISTED ESOP OPTIONS.</p> <p>(B) GRANTING OF UNLISTED ESOP OPTIONS.</p> <p>(C) LAPSING OF UNLISTED ESOP OPTIONS.</p>

7 Dates of entering +securities into uncertificated holdings or despatch of certificates

(A) ENTERED AUGUST 7, 2009 CERTIFICATES ISSUED AS SOON AS PRACTICABLE THEREAFTER.
(B) AUGUST 6, 2009
(C) AUGUST 6, 2009

Number	+Class
282,718,551	ORD SHARES
22,153,313	OPTIONS EXPIRING MARCH 12, 2010, EXERCISABLE AT \$1.18
10,950,124	OPTIONS EXPIRING 8 FEB 2012, EXERCISABLE AT \$0.68

Number	+Class
24,823,396	ESOP AND AGM APPROVED OPTIONS EXPIRING AT VARIOUS DATES AND EXERCISABLE AT VARIOUS PRICES

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required?

N/A

12 Is the issue renounceable or non-renounceable?

N/A

13 Ratio in which the +securities will be offered

N/A

14 +Class of +securities to which the offer relates

N/A

15 +Record date to determine entitlements

N/A

+ See chapter 19 for defined terms.

-
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? N/A
- 17 Policy for deciding entitlements in relation to fractions N/A
- 18 Names of countries in which the entity has ⁺security holders who will not be sent new issue documents
Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7. N/A
- 19 Closing date for receipt of acceptances or renunciations N/A

- 20 Names of any underwriters N/A
- 21 Amount of any underwriting fee or commission N/A
- 22 Names of any brokers to the issue N/A
- 23 Fee or commission payable to the broker to the issue N/A
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺security holders N/A
- 25 If the issue is contingent on ⁺security holders' approval, the date of the meeting N/A
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled N/A
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders N/A
- 28 Date rights trading will begin (if N/A

	applicable)	<input type="text"/>
29	Date rights trading will end (if applicable)	<input type="text" value="N/A"/>
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	<input type="text" value="N/A"/>
31	How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	<input type="text" value="N/A"/>
32	How do +security holders dispose of their entitlements (except by sale through a broker)?	<input type="text" value="N/A"/>
33	+Despatch date	<input type="text" value="N/A"/>

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents N/A

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000

+ See chapter 19 for defined terms.

10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)	<input type="text"/>	<input type="text"/>

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Date: August 10, 2009

Print name: James Campbell, Company Secretary

== == == == ==